A Pilot Study of the Humoral Response Against the AntiSense Protein (ASP) in HIV-1-Infected Patients
Juliette Savoret, Nathalie Chazal, Jean-Pierre Moles, Edouard Tuaillon, Faroudy Boufassa, Laurence Meyer, Camille Lecuroux, Olivier Lambotte, Philippe van de Perre, Jean-Michel Mesnard, et al.

To cite this version:
Juliette Savoret, Nathalie Chazal, Jean-Pierre Moles, Edouard Tuaillon, Faroudy Boufassa, et al.. A Pilot Study of the Humoral Response Against the AntiSense Protein (ASP) in HIV-1-Infected Patients. Frontiers in Microbiology, Frontiers Media, 2020, 11, pp.20. 10.3389/fmicb.2020.00020. hal-02453818

HAL Id: hal-02453818
https://hal.archives-ouvertes.fr/hal-02453818
Submitted on 6 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
The existence of an antisense Open Reading Frame (ORF) that encodes a putative AntiSense Protein (ASP) on the proviral genome of Human Immunodeficiency Virus type 1 (HIV-1) was a source of debate for 30 years. During the last years, some progresses have been made to characterize the cellular immune response against ASP in HIV-1 seropositive patients. However, no tools were available for the detection of antibodies to ASP in the plasma of HIV-1-infected patients during the natural course of the infection. The aim of our study was to develop a Luciferase Immuno-Precipitation System (LIPS) to monitor the quantitative detection of ASP-specific antibodies in the plasma of HIV-1-infected patients [antiretroviral therapy (ART) naive-patients, patients under ART and HIV-1 controllers], patients who discontinued antiretroviral drugs (ARV). We further used this approach to delineate the epitopes of ASP targeted by antibodies. Antibodies directed against ASP were detected in 3 out of 19 patients who discontinued ARV (15%) and in 1 out of 10 ART-naive patients (10%), but were neither detected in HIV-1 infected patients under ART nor in HIV-1 controllers. Individual variations in levels of ASP-specific antibodies were detected overtime. Both the conserved prolin-rich motif and the core 60–189 region of ASP were found to be essential for antibody recognition in the four patients tested positive for anti-ASP antibodies, who were all untreated at the time of sampling. Moreover, for two of these patients, increased levels of ASP-specific antibodies were observed concomitantly to viremia declines. Overall, our method may represent a useful tool to detect a humoral response to ASP in HIV-1-infected patients, which allowed us to confirm the expression of ASP during the course of HIV-1 infection. Further studies will be needed to fully characterize the humoral response to ASP in HIV-1-infected patients.

Keywords: HIV-1, antisense protein, antibodies, luciferase immuno-precipitation system, viremia
INTRODUCTION

The existence of a conserved Open Reading Frame (ORF) located on the antisense strand of the proviral genome of the Human Immunodeficiency Virus type 1 (HIV-1) was first suggested in 1988 (Miller, 1988). In this pioneer study, the antisense ORF was proposed to encode for a highly hydrophobic protein of 189 amino acids, later named AntiSense Protein (ASP). The very first detection of ASP in HIV-1-infected cells was achieved by the group of C. Vaquero in 2002 (Briquet and Vaquero, 2002). The same year, our group demonstrated the existence of Human-T-leukemia Virus Type 1 (HTLV-1) B-ZIP Factor (HBZ), another antisense retroviral protein (Gaudray et al., 2002). Following this discovery, we and others have investigated the antisense transcriptional activity of HIV-1 (Michael et al., 1994; Landry et al., 2007; Laverdure et al., 2012; Arpin-André et al., 2014) and studied ASP both in vitro and ex vivo. In collaboration with others, we thus successively reported (i) the detection of ASP at the plasma membrane of transfected cells (Clerc et al., 2011), (ii) the involvement of ASP in the autophagic flux of ASP-expressing cells (Torresilla et al., 2013) and importantly, (iii) the detection of a cytotoxic T CD8+ response directed against several domains of ASP in HIV-1 infected patients (Bet et al., 2015). In addition, our group recently showed the concomitant emergence of the 10th gene of HIV-1, the asp gene, with the pandemic group M of HIV-1, as well as the existence of a selection pressure acting to maintain asp within this group (Cassan et al., 2016). Altogether, these findings brought us to argue that ASP might be involved in the spreading or in the virulence of HIV-1. However, the role endorsed by ASP in the pathophysiology of HIV-1 infection and its underlying cellular mechanisms remain to be unraveled. One way to demonstrate the in vivo expression and immunogenicity of ASP, and to assess when ASP is expressed during the course of HIV-1 infection consists in detecting the humoral response elicited against ASP in infected patients. The study from the group of C. Vaquero conducted in 1995 previously revealed by western blot an in vitro translated ASP after immunoprecipitation by several serum samples from HIV-1-infected individuals, suggesting the existence of antibodies targeting ASP in vivo (Vanhée-Brossollet et al., 1995). However, these promising results have never been reproduced nor confirmed by any other study. In the present study, we developed a specific and quantitative luminescent assay to detect antibodies targeting ASP in a panel of plasma samples from HIV-1-infected patients under antiretroviral therapy (ART), ART-naïve or who discontinued antiretroviral drugs (ARV). The LIPS assay presents several advantages. First, the recombinant proteins used in LIPS are obtained from a soluble crude cell lysate extracted from transfected cells, which prevents complex purification protocols. Second, the method used to obtain the recombinant antigens allows the use of native, non-reducing conditions for the antigens. Third, LIPS is a fluid phase immunoassay using antigens in their native conformation and is well suited to detect antibodies directed against linear and conformational epitopes (Burbelo et al., 2015). In the patients tested positive for ASP-specific antibodies, we further delineated the domains of ASP targeted by the antibodies by using ASP deletion mutants. In conclusion, in this study, we provided evidence of the existence of antibodies directed against ASP in vivo, we gave insights into the targeted epitopes of ASP, and, for the first time, we described the humoral response against ASP in the plasma of HIV-1-infected individuals.

MATERIALS AND METHODS

Human Plasma Samples

ANRS 12174 Trial

Subjects were HIV-1-infected breastfeeding women from Burkina Faso whose infants were enrolled in the PROMISE-PEP trial. All mothers received AZT during pregnancy and labor but they were not eligible for ART post-partum according to national recommendations at the period the trial was conducted (above 350 CD4 cell/μL of blood) (Nagot et al., 2016). Written informed consents were obtained from the mother or the legal representative prior to enrollment (NCT00640263). Plasma samples were screened at week 38 post-partum and at intermediate time points when necessary. The study was conducted according to the sponsor (Agence Nationale de Recherche sur le Sida et les hépatites virales; ANRS) ethic charter, Good Clinical Practices and the principles of the Helsinki declaration. The protocol was approved by the National Ethic Committee (n° 2008-0039).

ANRS CO2 SEROCO Cohort

Subjects, enrolled from 1988 to 1995 (i) were infected no more than 12 months prior to enrollment and (ii) were free of AIDS related diseases at inclusion (Hubert et al., 2000). No ART were received before inclusion and during the study until 1996. A follow-up was performed every 6 months until 2009. A written informed consent was obtained from patients, in line with the guidelines formulated by local ethical committees.

ANRS HIV Controller C021 CODEX Cohort

Enrolled subjects met the following criteria: (i) naive for ART, (ii) seropositive for at least 5 years before enrollment, and (iii) with a viral load below 400 HIV-1 RNA copies/mL in the five consecutive measurements before inclusion (Lambotte et al., 2005; Sáez-Cirión et al., 2007) Follow-up was performed at least once a year for 6 years. All patients gave a written informed consent. The C021 CODEX cohort was approved by the Ethics Review Committee of Ile de France VII and performed in compliance with the tenets of the Declaration of Helsinki.

Patients Under ART

We used plasma isolated from total blood samples collected from 20 patients under ART during their follow-up at the University Hospital of Montpellier. Subjects enrolled in the cohort provided written informed consent. The study was then approved by Institutional Ethics Committee (RCB n° 2011-A01566-35, AC-2011-1405).

Uninfected Donors

Plasma samples were collected from French seronegative blood donors (Etablissement Français du Sang) and from
breastfeeding, seronegative women from Zambia. The study was approved by the Excellency in Research Ethics and Science Converge Institutional Review Board (00005948 IRB number) in Lusaka, Zambia.

**Antigens Preparation**

Flag-nanoluciferase cDNA (kindly gifted by Dr. Olivier Moncorgé, IRIM) was fused with the codon-optimized cDNA sequence of full-length ASP that has been previously described (Torresilla et al., 2013), or with ASP deletion mutants. The sequences of nano-ASP and of the 26–189 and 60–189 mutants were generated by overlapping PCR from the nanoluciferase and ASP cDNA sequences. For nano-ASP, we used the following primers: nanoluciferase forward 5′-ACGTGAATTCCGCCGCCATGGAAGTCCGACGATCAGCAAGTTCCTTCACA CTCGAAAG-3′ and reverse 5′-CAGCGGTGGGGATGGGGGCCTTGTTCCT-3′, ASP forward 5′-GACCGATCTGGGCGGCGTCCAGGCGCTGAGTCCCAACCCACGAGGATGCAGTGA-3′ and reverse 5′-ACTGCGAATTCACTGCAAGCTCCACGCAGGAGTTCAGCAGTGA-3′. For the 26–189 mutant, the following primer sets were used: nanoluciferase forward 5′-ACGTGAATTCGCCGCCATGGAAGTCCGACGATCAGCAAGTTCCTTCACA CTCGAAAG-3′ and reverse 5′-CAGGGCGGTACTCGAGCCGCTGGAGCCCGCCAGAATGCGTTC-3′; ASP forward 5′-GGCGGTGGGGATGGGGGCCTTGTTCCT-3′ and reverse 5′-ATTACGGACAGTCAGCTCCATCGGAGTTCAGCAGTGA-3′. For the 60–189 mutant, the following primer sets were used: nanoluciferase forward 5′-ACGTGAATTCGCCGCCATGGAAGTCCGACGATCAGCAAGTTCCTTCACA CTCGAAAG-3′ and reverse 5′-CAGGGCGGTACTCGAGCCGCTGGAGCCCGCCAGAATGCGTTC-3′; ASP forward 5′-GGCGGTGGGGATGGGGGCCTTGTTCCT-3′ and reverse 5′-ATTACGGACAGTCAGCTCCATCGGAGTTCAGCAGTGA-3′. For the 1–62 and 1–141 nano-ASP deletion mutants, the following primer sets were used: nanoluciferase forward 5′-ACGTGAATTCGCCGCCATGGAAGTCCGACGATCAGCAAGTTCCTTCACA CTCGAAAG-3′ and reverse 5′-CAGGGCGGTACTCGAGCCGCTGGAGCCCGCCAGAATGCGTTC-3′; ASP forward 5′-GGCGGTGGGGATGGGGGCCTTGTTCCT-3′ and reverse 5′-ATTACGGACAGTCAGCTCCATCGGAGTTCAGCAGTGA-3′. The 1–62 and 1–141 nano-ASP deletion mutants were generated from the full-length cDNA sequence of nano-ASP with the forward primer 5′-ACGTGAATTCGCCGCCATGGAAGTCCGACGATCAGCAAGTTCCTTCACA CTCGAAAG-3′ and the reverse primer 5′-CAGGGCGGTACTCGAGCCGCTGGAGCCCGCCAGAATGCGTTC-3′; ASP forward 5′-GGCGGTGGGGATGGGGGCCTTGTTCCT-3′ and reverse 5′-ATTACGGACAGTCAGCTCCATCGGAGTTCAGCAGTGA-3′. The 1–62 and 1–141 nano-ASP deletion mutants were generated from the full-length cDNA sequence of nano-ASP with the forward primer 5′-ACGTGAATTCGCCGCCATGGAAGTCCGACGATCAGCAAGTTCCTTCACA CTCGAAAG-3′ and the reverse primer 5′-CAGGGCGGTACTCGAGCCGCTGGAGCCCGCCAGAATGCGTTC-3′; ASP forward 5′-GGCGGTGGGGATGGGGGCCTTGTTCCT-3′ and reverse 5′-ATTACGGACAGTCAGCTCCATCGGAGTTCAGCAGTGA-3′.

**RESULTS**

**Development of a Quantitative Assay to Detect Antibodies Against ASP in the Plasma of HIV-1-Infected Patients**

The LIPS allows for the detection of specific antibodies elicited against pathogens in patients (Burbelo et al., 2014, 2015). In this assay, a luciferase is fused to the antigen of interest, and plasma samples are incubated with cell lysates containing this fusion protein. After an immuno-precipitation step, the presence of antigen-specific antibodies in the plasma of patients is revealed by the luminescence signal emitted by the luciferase. To detect anti-ASP antibodies in the plasma of HIV-1 infected patients, we used a codon-optimized ASP derived from pNL4-3 fused to the nano-luciferase protein (nano-ASP). We first tested the assay with a monoclonal antibody targeting the residues 47 to 62 of ASP, and we obtained a luminescent signal proportional to the concentration of the anti-ASP monoclonal antibody added to the reaction, while no specific signal was obtained when using the nano-luciferase protein alone (Supplementary Figure S1). Therefore, we developed an assay that allows for the specific and quantitative immuno-precipitation of nano-ASP. Using LIPS assay, we then evaluated the presence of specific anti-ASP antibodies in the plasma samples of HIV-1-infected patients.

**Antibodies to ASP Are Detected in Untreated HIV-1-Infected Patients**

We assessed the presence of antibodies against ASP in the plasma from two groups of HIV-1 infected individuals: a group of European patients under ART and a group of African patients who discontinued ARV (Nagot et al., 2016). The group...
of African patients were pregnant women recruited for the ANRS 12174 clinical trial (Nagot et al., 2016). In this trial, women received zidovudine as prophylaxis for 4–16 weeks before delivery followed by a combination of zidovudine and lamivudine for 7 days after delivery (Table 1). Maternal prophylaxis was stopped at day 7 after patients gave birth, and plasma samples were then regularly collected up to 41 weeks following ARV cessation. The results presented Figure 1 were obtained on plasma samples collected from the African patients 37 weeks after ARV cessation (W37).

We used two groups of uninfected individuals as a control: a group of breastfeeding women from Africa, and a group of European individuals (Figure 1 and Table 1). Using both control groups, the cut-off for positive anti-ASP response was set-up at 48,000 RLU (see section “Materials and Methods”). In the plasma of patients under ART, we observed a signal similar to that obtained in the plasma of the uninfected individuals. However, we observed a positive signal in 3 of the 19 plasma samples collected from the African patients at W37, indicating the presence of antibodies against ASP in the plasma of these three patients (patients #7, #9, and #16, Figure 1A). We then determined the titer of ASP-specific antibodies in the plasma of patients #7, #9, and #16 at W37 by performing serial dilutions of the plasma samples (Figure 1B). Patients #7 and #9 displayed ASP-antibody titers of 1/200 and 1/100, respectively. In accordance with its higher luminescence signal, the patient #16 showed an ASP-antibody titer of 1/800. Altogether, we detected antibodies against ASP in 3 out of the 19 HIV-1-infected patients (15%) who discontinued ARV, but not in patients under ART.

### Antibody Response to ASP Is Dynamic Over Months

To evaluate the evolution of the antibody response to ASP overtime, we searched for ASP-specific antibodies in the plasma samples of Pat #7, #9, and #16 which were collected at different times from ARV cessation to W37, as previously mentioned (Nagot et al., 2016) (Figure 2 and Table 1). Interestingly, the anti-ASP antibody response fluctuated differently following

### Table 1 | Immuno-virological parameters of the patients belonging to the cohort ANRS 12174 (PROMISE-PEP study).

| Patient | Ethnical origin | ARV received during pregnancy | Duration of ARV received (weeks) | Time after ARV cessation (weeks) | Viremia (copies of HIV-1 RNA/mL of blood) | CD4 T cells/µL of blood |
|---------|----------------|------------------------------|---------------------------------|---------------------------------|------------------------------------------|------------------------|
| P#1     | African        | ZDV                          | 11                              | 37                              | 114,600                                  | 403                    |
| P#2     | African        | ZDV                          | 16                              | 37                              | 609,800                                  | 536                    |
| P#3     | African        | ZDV                          | 11                              | 37                              | NA                                       | NA                     |
| P#4     | African        | ZDV                          | 14                              | 37                              | 43,980                                   | 522                    |
| P#5     | African        | ZDV                          | 10                              | 37                              | NA                                       | NA                     |
| P#6     | African        | ZDV                          | 8                               | 37                              | 33,980                                    | 395                    |
| P#7     | African        | ZDV                          | 7                               | 0                               | 17,280                                    | NA                     |
| P#8     | African        | ZDV                          | 6                               | 37                              | 249,200                                  | 536                    |
| P#9     | African        | ZDV                          | 7                               | 0                               | 50,320                                    | NA                     |
| P#10    | African        | ZDV                          | 13                              | 37                              | 279,400                                  | 367                    |
| P#11    | African        | ZDV                          | 5                               | 25                              | NA                                       | NA                     |
| P#12    | African        | ZDV                          | 0                               | 37                              | 1712                                     | 728                    |
| P#13    | African        | ZDV                          | 13                              | 37                              | 9,069                                     | 4057                   |
| P#14    | African        | ZDV                          | 8                               | 37                              | 318,700                                   | 729                    |
| P#15    | African        | ZDV                          | 14                              | 37                              | 250,400                                   | 545                    |
| P#16    | African        | ZDV                          | 4                               | 0                               | Undetectable                             | NA                     |
| P#17    | African        | ZDV                          | 11                              | 37                              | 17,210                                    | 847                    |
| P#18    | African        | ZDV                          | 6                               | 37                              | 112,800                                   | 372                    |
| P#19    | African        | ZDV                          | 2                               | 37                              | NA                                       | NA                     |

ARV, Antiretroviral agent; ZDV, zidovudine. NA, not available.
ARV cessation in the plasma of these three patients. In the plasma of Pat #16, the response to ASP declined overtime, though it remained the highest antibody response to ASP among the three patients, whatever the time points considered. On the contrary, anti-ASP response remained quite stable in the plasma of Pat #9 during the follow-up. For Pat #9 and #16 plasma, antibodies against ASP were detected at the time of ARV cessation, while they only became detectable 25 weeks after ARV cessation in Pat #7. Levels of antibodies to ASP then increased up to 37 weeks post-ARV cessation in Pat #7, concomitantly to a decrease in viral loads. Of note, the plasma of Pat #16 displayed sustained low viremia and increased levels of CD4+ T cells between ARV cessation and W37 (Figure 2 and Table 1), while the level of CD4+ T cells remained stable for Pat #7 and #9 during the follow-up. Overall, the antibody response in the plasma of Pat #7, #9, and #16 to ASP fluctuated after ARV cessation in a patient specific manner.

Antibodies to ASP Are Not Detected in Patients Under ART

Patients under ART did not show any specific signal for anti-ASP antibodies (Figure 1A). To further investigate the fluctuations of the antibody response to ASP upon ART initiation, we performed LIPS assay on the plasma of 10 patients from the French ANRS SEROCO cohort (Multicentric Cohort of HIV Positive Patients), before and after they initiated ART (Hubert et al., 2000) (Figure 3A and Table 2). Strikingly, we detected a strong signal in the plasma of 1 of the 10 patients prior to ART (Pat #20 at 2.5 years post-enrollment, i.e., 3 years before ART initiation), but we did not detect any specific signal in the plasma of this same patient 8 years after ART initiation (Table 2). To further characterize the response developed against ASP in Pat #20, we conducted LIPS assay on plasma samples collected at two additional times post-enrollment, respectively 5 years before and 2 years after ART.
initiation (Figure 3B and Table 2). Interestingly, the loss of antibody response to ASP observed in the plasma of Pat #20 was already observed 2 years after ART initiation and seemed to be sustained for up to 8 years. Besides, antibodies to ASP were barely detectable in this patient at enrollment (5 years before ART), while increased levels were detected 2.5 years post-enrollment (i.e., 3 years before ART). As patients from the SEROCO cohort were infected no more than 1 year prior to their enrollment (Lambotte et al., 2005; Sáez-Cirión et al., 2007), these data suggest that levels of antibodies to ASP kept increasing following the first year of infection in Pat #20. Besides, as observed for Pat #7 (Figure 2), increased levels of anti-ASP antibodies in the plasma of Pat #20 were detected concomitantly to a phase of viremia decline. Altogether, these results suggest that the magnitude of the humoral response to ASP decreases under ART.

Antibodies to ASP Are Not Detected in Aviremic HIV Controllers

In plasma samples of Pat #7 and #20, increased levels of anti-ASP antibodies were observed during a phase of viremia decline, which could indicate that antibodies targeting ASP contributed to the immune response elicited against HIV-1.
FIGURE 3 | Anti-ASP antibody response is not detected after ART initiation in Pat #20. (A) The presence of antibodies against ASP was monitored in the plasma of 10 patients from the SEROCO cohort before and after they initiated ART. Time elapsed between the two time points differ for each patient and goes from 7.5 to 13 years. Each patient is identified by a different symbol. Results obtained with the French seronegative control group (N = 20) presented Figure 1 are also shown. Signal is expressed as Relative Light Units (RLU). Data shown are the mean of the median of three independent experiments performed in triplicates. (B) The anti-ASP antibody response and viremia overtime were monitored in Pat #20 at four different times post-inclusion (at 2.5- and 13.5-years post-inclusion as showed in panel (A), at inclusion and at 7 years post-inclusion). Data shown represent the median (plus min and max values) of one representative experiment performed in triplicates. The star indicates initiation of ART. Values of viremia (number of HIV-1 RNA copies/mL) previously measured in the context of the SEROCO cohort are also represented. Dotted line represents the cut-off value (48,000 RLU).

To test this hypothesis, we investigated the presence of ASP-specific antibodies in the plasma of HIV-1 controllers (HIC) enrolled in the French ANRS CODEX cohort (Multicentric cohort of HIV-1 patients with extreme progression profiles; Table 3) (Lambotte et al., 2005; Sáez-Cirión et al., 2007). HIC are patients naturally displaying long-term control of viremia (below 400 HIV RNA copies/mL in the CODEX cohort). As we showed above that the antibody response to ASP fluctuated overtime in patients (Figures 2, 3B), we assessed anti-ASP antibodies in the plasma samples collected from these patients at two different times post-enrollment, 2 years apart (Table 3). As showed Figure 4, only a background signal was observed in the plasma of these patients, indicating that they did not display antibodies to ASP at any of the two time points that we tested. Of note, we cannot totally exclude the possibility that these patients presented anti-ASP antibodies at earlier stages of the infection, but according to our results, ASP-specific antibodies probably did not contribute to set up the control of viremia in these patients.

Antibodies Target the 26–141 Region of ASP

As a consequence of its overlapping position to env in the proviral genome of HIV-1, asp encodes for a protein that possesses two highly variable regions (V4 and V5, Figure 5) located at its C-terminal extremity. Conversely, the N-terminal extremity of ASP displays several well-conserved domains: two cysteine triplets and a prolin-rich motif. To delineate the domains of ASP which are targeted by antibodies, we conducted LIPS on the plasma collected from Pat #7, #9, #16, and #20 with nano-ASP mutants deleted from different domains of ASP (Figure 5 and Supplementary Figure S2). The deletion of the cysteine triplets (26ñ189 mutant) and of the C-terminal region (1ñ141 mutant) encompassing the highly variable motif V4 of ASP did not decrease the signal in any of the plasma tested, indicating that none of these regions are targeted by the antibodies that are present in the plasma of Pat #7, #9, #16, and #20. On the contrary, the signal was either reduced (Pat #9 and #16) or totally suppressed (Pat #7 and #20) with the ASP 60ñ189 mutant lacking the prolin-rich motif. In all the patients, a strong decline was observed when using the prolin-rich motif as antigen (1ñ62 mutant), although the decline was less important for Pat #16 than for the three other patients. These results suggest that both the 26–60 region encompassing the PxxP motif and the 60–141 core region of ASP encompassing the highly variable motif V5 are involved in the main epitope of ASP, either directly or indirectly by allowing the proper folding of the epitope.

DISCUSSION

In our study, we developed a specific and quantitative luminescent assay to assess the presence of antibodies directed against ASP in the plasma of HIV-1-infected patients. Using this approach, we found anti-ASP antibodies in patients who discontinued ARV (3 of 19) and in ART-naïve patients (1 of 10).
TABLE 2 | Immuno-virological parameters of the patients belonging to the cohort ANRS CO2 SEROCO.

| Patient | Ethnical origin | Time post-inclusion (years) | ART | Viremia (copies of HIV-1 RNA/mL of blood) | CD4 T cells/µL of blood |
|---------|-----------------|-----------------------------|-----|------------------------------------------|------------------------|
| Pat#20  | European        | 0                           | No  | 125430                                   | 1200                   |
|         |                 | 2,5                         | No  | 4931                                     | 690                    |
|         |                 | 7                           | AZT-DDC | 67722                                   | 139                    |
|         |                 | 13,5                        | AZT-DDC-InR | Undetectable | 58                     |
| Pat#21  | European        | 3                           | No  | 413                                      | 413                    |
|         |                 | 15                          | 3TC-ABC-NVP | 572                                      | 572                    |
| Pat#22  | European        | 2,5                         | No  | 805                                      | 805                    |
|         |                 | 8,5                         | 3TC-AZT-IDV | 171                                      | 171                    |
| Pat#23  | European        | 3,5                         | No  | 514                                      | 514                    |
|         |                 | 15                          | AZT-DDI | 558                                      | 558                    |
| Pat#24  | European        | 2,5                         | No  | 720                                      | 720                    |
|         |                 | 10,75                       | AZT-DDC-SQV | 768                                      | 768                    |
| Pat#25  | European        | 1,5                         | No  | 791                                      | 791                    |
|         |                 | 14,5                        | ABC-DDI-EFV | 649                                      | 649                    |
| Pat#26  | European        | 2,5                         | No  | 600                                      | 600                    |
|         |                 | 12,5                        | D4T-NVP-SqR | 1087                                     | 1087                   |
| Pat#27  | European        | 5                           | No  | 350                                      | 350                    |
|         |                 | 13                          | 3TC-ABC-AZT | 776                                      | 776                    |
| Pat#28  | European        | 4,5                         | No  | 785                                      | 785                    |
|         |                 | 12                          | 3TC-D4T | 681                                      | 681                    |
| Pat#29  | European        | 4,5                         | No  | 500                                      | 500                    |
|         |                 | 13                          | 3TC-D4T | 652                                      | 652                    |

AZT, Azidothymidine; DDC, Dideoxycytidine; lnR, Lopinavir; 3TC, Lamivudine; ABC, Abacavir; NVP, Nevirapine; 3TC-AZT-IDV, Indinavir; DDI, Didanosine; SQV, Saquinavir; EFV, Efavirenz; SqR, Saquinavir; D4T, Stavudine.

By contrast, antibodies to ASP were detected neither in aviremic patients under ART nor in ART-naive aviremic HIV-1 controllers. The analysis of ASP-targeted domains showed that both the conserved prolin-rich motif and the core region (60–141) encompassing the highly variable motif V5 are involved in ASP recognition by antibodies. So far, the only variation of ASP that has been specifically associated with a viral subtype (HIV-1 subtype A) is a N-terminal deletion (residues 1–26) (Cassan et al., 2016). Besides, the C-terminal domain contains most of the inter- and intra-individual variations (Cassan et al., 2016). Neither the N-terminal nor the C-terminal extremities of ASP seemed to be targeted by antibodies, which thus appear to be dispensable to elicit anti-ASP antibody response. However, we cannot exclude that, in our investigation, the targeting of the variable C-terminal region of ASP might have been underestimated by the use of an ASP antigen (derived from BRU/LAV) whose sequence might differ from the ones found in patients.

In our study, anti-ASP antibodies were detected in 10–15% of the HIV-1-infected individuals, which seems less than previously suggested by the study of C. Vaquero, a least for patients in advanced stages of infection (Vanhee-Brossollet et al., 1995). However, humoral responses to other auxiliary and regulatory proteins of HIV-1 in infected subjects ranged from 12% (Tat; Rezza et al., 2005) to 25–26% (Vif and Vpr; Reiss et al., 1990; O’Neil et al., 1997), and up to 43% (Vpu; Reiss et al., 1990). The frequency of anti-ASP antibody response is also consistent with previous studies showing humoral responses against HBZ in 10% of the HTLV-1 infected subjects (Enose-Akahata et al., 2013; Shiohama et al., 2016). The CD8+ T cell response targeting ASP was described in approximately 30% of the patients (Berger et al., 2015; Bet et al., 2015). This higher frequency might be inferred to the targeting by CD8+ T cells of highly conserved linear epitopes from intracellular antigens, contrary to antibodies which target extracellular antigens. Humoral responses to HIV-1 Gag, Pol and Env proteins were described to be dependent of HIV-1 replication and to strongly decline during ART (Voltersvik et al., 2003; Killian et al., 2006; Zhang et al., 2017; Delagreverie et al., 2019). In line with these results, we did not detect any antibodies to ASP in aviremic patients under ART. In addition, antibodies to ASP were no longer detected in Pat #20 at two different times after ART initiation, further suggesting that the prolonged aviremia under ART lead to a decrease of antibody responses to ASP. However, for Pat #9 and #16 who presented antibodies to ASP at the earliest time point tested after ARV cessation, we can speculate a persistence of this response regarding the short duration of their ARV (7 and 4 weeks, respectively). As suggested by the lack of detection of antibodies targeting ASP in the plasma of HIV-1 controllers in our study, a detectable level of viral replication might be needed to induce a humoral response to ASP. Interestingly, ASP was recently described at the membrane of viral particles released by chronically infected cells following their in vitro reactivation (Affram et al., 2019). If ASP is indeed present at the surface of viral particles in vivo, it might partially explain why we did not detect antibodies against ASP in patients displaying very low or undetectable viral loads. However, this hypothesis is challenged by the fact that we observed a...
TABLE 3 | Immuno-virological parameters of the patients belonging to the cohort ANRS HIV Controller CO21 CODEX.

| Patient | Ethnical origin | Time post-inclusion (years) | Viremia (copies of HIV-1 RNA/mL of blood) | CD4 T cells/µL of blood |
|---------|-----------------|----------------------------|------------------------------------------|------------------------|
| Pat#30  | European        | 1                          | <20                                      | 1238                   |
|         |                 | 3                          | <20                                      | 1917                   |
| Pat#31  | European        | 0                          | <50                                      | 809                    |
|         |                 | 2                          | <40                                      | 874                    |
| Pat#32  | European        | 0                          | <10                                      | 790                    |
|         |                 | 2                          | <10                                      | 1153                   |
| Pat#33  | African (Maghreb)| 4                          | <40                                      | 1216                   |
|         |                 | 6                          | <40                                      | 1320                   |
| Pat#34  | European        | 2                          | 41                                       | 478                    |
|         |                 | 4                          | <40                                      | 554                    |
| Pat#35  | European        | 3                          | <40                                      | 644                    |
|         |                 | 5                          | 42                                       | 539                    |
| Pat#36  | European        | 1                          | <20                                      | 676                    |
|         |                 | 3                          | <20                                      | 628                    |
| Pat#37  | European        | 3                          | <40                                      | 452                    |
|         |                 | 6                          | <40                                      | 630                    |
| Pat#38  | European        | 0                          | <20                                      | 627                    |
|         |                 | 2                          | <20                                      | 682                    |
| Pat#39  | European        | 0                          | <40                                      | 1224                   |
|         |                 | 2                          | <40                                      | 1482                   |
| Pat#40  | African (Maghreb)| 0                          | <40                                      | 421                    |
|         |                 | 2                          | <40                                      | 666                    |
| Pat#41  | European        | 1                          | <20                                      | 712                    |
|         |                 | 3                          | 23                                       | 979                    |
| Pat#42  | European        | 2                          | <20                                      | 1382                   |
|         |                 | 4                          | <20                                      | 1509                   |
| Pat#43  | European        | 2                          | <40                                      | 966                    |
|         |                 | 4                          | <40                                      | 851                    |
| Pat#44  | European        | 1                          | <40                                      | 570                    |
|         |                 | 3                          | <30                                      | 600                    |
| Pat#45  | European        | 2                          | <20                                      | 780                    |
|         |                 | 4                          | <20                                      | 1740                   |
| Pat#46  | European        | 0                          | <20                                      | 989                    |
|         |                 | 2                          | <20                                      | 761                    |
| Pat#47  | European        | 0                          | <20                                      | 584                    |
|         |                 | 2                          | <20                                      | 693                    |
| Pat#48  | European        | 3                          | <20                                      | 704                    |
|         |                 | 5                          | <40                                      | 900                    |
| Pat#49  | European        | 0                          | <40                                      | 735                    |
|         |                 | 2                          | <35                                      | 836                    |

This could also indicate that the in vivo production of ASP occurs when viral production decreases, contrary to what was suggested by the study of Affram et al. (2019), but in line with a previous study which suggested that ASP is rather expressed during the chronic phase than during the acute phase of the disease (Bet et al., 2015). Besides, we recorded an increase in ASP-specific antibody titers during the 2.5 years following enrollment in Pat #20, further suggesting that antibody response to ASP is developed after acute infection. Though a recent study reported the concomitant expression of sense and antisense transcripts in infected cells (Mancarella et al., 2019), several studies conducted by our group and by others showed that antisense transcription preferentially occurs in non-producing infected cells (Landry et al., 2007; Kobayashi-Ishihara et al., 2012; Laverdure et al., 2012; Saayman et al., 2014; Zapata et al., 2017). This consideration is of outstanding interest as several studies previously proposed antisense transcription as a common feature of viral latency (Landry et al., 2007; Kobayashi-Ishihara et al., 2012; Laverdure et al., 2012; Saayman et al., 2014; Zapata et al., 2017). Altogether, we developed a specific and quantitative assay that allows us to evaluate anti-ASP antibodies in the plasma of HIV-1-infected patients. Our results provide the first confirmation of the study conducted in 1995 by C. Vaquero’s group (Vanhée-Brossollet et al., 1995) and describe individual variations in ASP-specific antibody titers during the infection course. Though observed on a small number of subjects, the results of our pilot evaluation point the importance to study ASP and its antibody response during the different stages of HIV-1 infection. In the future, it would be of great interest to increase the number of serum samples (from HIV-1 negative and positive individuals) tested and to study the long-term ASP-specific antibody response in untreated, chronically infected subjects and to assess its potential impact on disease outcomes.
Patient antibodies target the 26–141 core region of ASP encompassing the V5 and prolin-rich motifs. (A) Scheme of nano-ASP mutants: CCC, cysteine triplets; PxxP, prolin-rich motif; TM, potential transmembrane domain; V4/V5, highly variable motifs 4 and 5. The numbers indicate amino acid positions in ASP.

(B) LIPS was conducted with nano-ASP mutants on the plasma collected from Pat #7, #9, #16 (collected 37 weeks after ARV cessation), and #20 (collected 2.5 years after enrollment). For each mutant, the signal was normalized by subtracting the signal obtained with the nanoluciferase alone for the same plasma sample. The resulting normalized luminescence is expressed as the percentage of the signal obtained with the full-length form of nano-ASP. Data shown represent the median of the triplicates obtained from one representative experiment.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the ANRS 12174 trial: subjects were HIV-1-infected breastfeeding women from Burkina Faso whose infants were...
enrolled in the PROMISE-PEP trial. All mothers received AZT during pregnancy and labor but they were not eligible for ART post-partum according to national recommendations at the period the trial was conducted (above 350 CD4 cell/µL of blood) (Nagot et al., 2016). Written informed consents were obtained from the mother or the legal representative prior to enrollment (NCT00640263). Plasma samples were screened at week 38 post-partum and at intermediate time points when necessary. The study was conducted according to the sponsor (Agence Nationale de Recherche sur le Sida et les hépatites virales; ANRS) ethic charter, Good Clinical Practices and the principles of the Helsinki declaration. The protocol was approved by the National Ethics Committee (n° 2008-0039). ANRS CO2 SEROCO cohort: subjects, enrolled from 1988 to 1995 (i) were infected no more than 12 months prior to enrollment and (ii) were free of AIDS related diseases at inclusion (Hubert et al., 2000). No ART were received before inclusion and during the study until 1996. A follow-up was performed every 6 months until 2009. A written informed consent was obtained from patients, in line with the guidelines formulated by local ethical committees. ANRS HIV Controller CO21 CODEX cohort: Enrolled subjects met the following criteria: (i) naïve for ART; (ii) seropositive for at least 5 years before enrollment, and (iii) with a viral load below 400 HIV-1 RNA copies/mL in the five consecutive measurements before inclusion (Lambotte et al., 2005; Sáez-Cirión et al., 2007). Follow-up was performed at least once a year for 6 years. All patients gave a written informed consent. The CO21 CODEX cohort was approved by the Ethics Review Committee of Ile de France VII and performed in compliance with the tenets of the Declaration of Helsinki. Patients under ART: we used plasma isolated from total blood samples collected from 20 patients under ART during their follow-up at the University Hospital of Montpellier. Subjects enrolled in the cohort provided written informed consent. The study was then approved by the Institutional Ethics Committee (RCB n° 2011-A01566-35, AC-2011-1405). Uninfected donors: plasma samples were collected from French seronegative blood donors (Etablissement Français du Sang) and from breastfeeding, seronegative women collected from French seronegative blood donors (Etablissement Français du Sang) and from breastfeeding, seronegative women from Zambia. The study was approved by the Excellency in Research Ethics and Science Converge Institutional Review Board (00005948 IRB number) in Lusaka, Zambia. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

AG, J-MM, PV, and J-PM designed the study. JS performed all experiments with assistance of NC and AG. JS, NC, and AG analyzed the data and wrote the manuscript. J-PM, ET, and PV provided samples from the PROMISE-PEP cohort and the University Hospital of Montpellier. FB and LM provided samples from the SEROCO cohort. CL and OL provided samples from the CODEX cohort.

**FUNDING**

The work was supported by the Fondation pour la Recherche Médicale (FRM; Equipe FRM 20161136701). JS was supported by the University of Montpellier, the Centre Hospitalier Universitaire (CHU) de Montpellier and Sidaction (2018-1-FJC-11994). The Agence Nationale de la Recherche sur le Sida et les hépatites virales (ANRS) SEROCO cohort, ANRS CODEX cohort, and ANRS PROMISE-PEP study were funded by the ANRS.

**ACKNOWLEDGMENTS**

We are grateful to Nicolas Méda and David Rutagwera for organizing samples collection in Burkina Faso and Zambia, respectively. We thank Olivier Moncorgé (IRIM, CNRS) for providing the nanoluciferase coding sequence.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.00020/full#supplementary-material

**REFERENCES**

Affram, Y., Zapata, J. C., Gholizadeh, Z., Tolbert, W. D., Zhou, W., Iglesias-Ussel, M. D., et al. (2019). The HIV-1 antisense protein ASP is a transmembrane protein of the cell surface and an integral protein of the viral envelope. J. Virol. 93:e00574-19. doi: 10.1128/JVI.00574-19

Arpin-André, C., Laverdure, S., Barbeau, B., Gross, A., and Mesnard, J.-M. (2014). Construction of a reporter vector for analysis of bidirectional transcriptional activity of retrovirus LTR. Plasmid 74, 45–51. doi: 10.1016/j.plasmid.2014.06.001

Berger, C. T., Llano, A., Carlson, J. M., Brumme, Z. L., Brockman, M. A., Cedeño, S., et al. (2015). Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1. J. Virol. 89, 4015–4019. doi: 10.1128/JVI.03435-1414

Bet, A., Maze, E., Bansal, A., Sterrett, S., Gross, A., Graff-Dubois, S., et al. (2015). The HIV-1 Antisense Protein (ASP) induces CD8 T cell responses during chronic infection. Retrovirology 12:15. doi: 10.1186/s12977-015-0135-y

Briquet, S., and Vaquero, C. (2002). Immunolocalization studies of an antisense protein in HIV-1-infected cells and viral particles. Virology 292, 177–184. doi: 10.1006/viro.2001.1224

Burbelo, P. D., Bayat, A., Rhodes, C. S., Hoh, R., Martin, J. N., Fromentin, R., et al. (2014). HIV antibody characterization as a method to quantify reservoir size during curative interventions. J. Infect. Dis. 209, 1613–1617. doi: 10.1093/infdis/jit667

Burbelo, P. D., Lebovitz, E. E., and Notkins, A. L. (2015). Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl. Res. 165, 325–335. doi: 10.1016/j.trsl.2014.08.006

Cassan, E., Arigon-Chifolleau, A.-M., Mesnard, J.-M., Gross, A., and Gascuel, O. (2016). Concomitant emergence of the antisense protein gene of HIV-1 and of the pandemic. Proc. Natl. Acad. Sci. U.S.A. 113, 11537–11542. doi: 10.1073/pnas.1605739113

Clerc, I., Laverdure, S., Torresilla, C., Landry, S., Borel, S., Vargas, A., et al. (2011). Polarized expression of the membrane ASP protein derived from HIV-1
Detection of Anti-ASP Antibodies

Hubert, J. B., Burgard, M., Dussaix, E., Tamalet, C., Deveau, C., Le Chenadec, J., Gaudray, G., Gachon, F., Basbous, J., Biard-Piechaczyk, M., Devaux, C., and Enose-Akahata, Y., Abrams, A., Massoud, R., Bialuk, I., Johnson, K. R., Green, P. L., Delagreverie, H. M., Grude, M., Lambert-Niclot, S., Nere, M.-L., Jadand, C., Lambotte, O., Boufassa, F., Madec, Y., Nguyen, A., Goujard, C., Meyer, L., et al. (2007). Laverdure, S., Gross, A., Arpin-André, C., Clerc, I., Beaumelle, B., Barbeau, B., et al. (2012). HIV-1 antisense transcription is preferentially activated in primary monocyte-derived cells. J. Virol. 86, 13785–13789. doi: 10.1128/JVI.01723-1712

Mancarella, A., Procopio, F. A., Achsel, T., De Cripps, N., Foley, R. B., Corradin, G., et al. (2019). Detection of antisense protein (ASP) RNA transcripts in individuals infected with human immunodeficiency virus type 1 (HIV-1). J. Gen. Virol. 100, 863–876. doi: 10.1099/jgv.0.001244

Michael, N. L., Vahey, M. T., d’Arcy, L., Ehrenberg, P. K., Mosca, J. D., Rappaport, J., et al. (1994). Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat. J. Virol. 68, 979–987. doi: 10.1128/jvi.68.2.979-987.1994

Miller, R. H. (1988). Human immunodeficiency virus may encode a novel protein on the genomic DNA plus strand. Science 239, 1420–1422. doi: 10.1126/science.3347840

Nagot, N., Kankasa, C., Tumwine, J. K., Meda, N., Hofmeyr, G. J., Vallo, R., et al. (2016). Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet 387, 566–573.

O’Neil, C., Lee, D., Clevy, G., Johnson, M. A., and Emery, V. C. (1997). Prevalence of anti-vif antibodies in HIV-1 infected individuals assessed using recombinant baculovirus expressed vif protein. J. Med. Virol. 51, 139–144.

Reiss, P., Lange, J. M., de Rondt, A., de Wolf, F., Dekker, J., Danner, S. A., et al. (1990). Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 3, 115–122.

Rezza, G., Fiorelli, V., Dorrutti, M., Cicozzi, M., Tripiciano, A., Scoglio, A., et al. (2005). The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J. Infect. Dis. 191, 1321–1324. doi: 10.1086/428909

Sáez-Cirión, A., Lacabaratz, C., Lambotte, O., Versmisse, P., Urrutia, A., Boufassa, F., et al. (2007). HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U.S.A. 104, 6776–6781. doi: 10.1073/pnas.0611244104

Shiohama, Y., Naito, T., Matsuoka, T., Tanaka, R., Tomoyose, T., Takashima, H., et al. (2016). Absolute quantification of HTLV-1 basic leucine zipper factor (HBZ) protein and its plasma antibody in HTLV-1-infected individuals with different clinical status. Retrovirology 13:29. doi: 10.1186/s12977-016-0263-z

Torresilla, C., Larocque, É, Landry, S., Halin, M., Coulombre, Y., Masson, J.-Y., et al. (2013). Detection of the HIV-1 minus-strand-encoded antisense protein and its association with autophagy. J. Virol. 87, 5089–5105. doi: 10.1128/JVI.00225-213

Vanhée-Brossollet, C., Thoreau, H., Serpente, N., D’Aurill, L., Lévy, J.-P., and Vaquero, C. (1995). A natural antisense RNA derived from the HIV-1 env gene encodes a protein which is recognized by circulating antibodies of HIV+ individuals. Virology 206, 196–202.

Voltersvik, P., Albrechtsen, G., Ulvestad, E., Dyrhol-Riise, A. M., Sørensen, B., and Asjo, B. (2003). Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J. Acquir. Immune Defic. Syndr. 34, 358–367.

Zapata, J. C., Campilongo, F., Barclay, R. A., DeMarino, C., Iglesias-Ussel, M. D., Kashanchi, F., et al. (2017). The Human Immunodeficiency Virus 1 ASP RNA promotes viral latency by recruiting the Polycomb Repressor Complex 2 and promoting nucleosome assembly. Virology 506, 34–44. doi: 10.1016/j.virology.2017.03.002

Zhang, W., Morshed, M. M., Noyan, K., Russom, A., Sonnerborg, A., and Neogi, U. (2017). Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy. Sci. Rep. 7:6666.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Savoret, Chazal, Moles, Tuallon, Boufassa, Meyer, Lecroux, Lambotte, Van De Perre, Mesnard and Gress. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.